Hospital Pharmacy presents a new feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest will be abstracted monthly regarding a broad scope of topics.
Get full access to this article
View all access options for this article.
References
1.
PatoleS., RaoS., DohertyD.Erythromycin as a prokinetic agent in preterm neonates: a systematic review.Arch Dis Child Fetal Neonatal Ed.2005; [Epub ahead of print].
2.
NestaasE., BangstadJ., SandvikL., WathneK.O.Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis.Arch Dis Child Fetal Neonatal Ed.2005; [Epub ahead of print].
3.
SimonS.R., MajumdarS.R., ProsserL.A., Salem-SchatzS.Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial.Am J Med.2005; 118(6): 521–528.
4.
JohnstonJ.A., Brill-EdwardsP., GinsbergJ.S., PaukerS.G.Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.Am J Med.2005; 118(5): 503–514.
5.
TitchenT., CranswickN., BeggsS.Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a pediatric hospital.Br J Clin Pharmacol.2005; 59(6): 718–723.
6.
New antimicrobial agents approved by the US Food and Drug Administration in 2004 and new indications for previously approved agents.Antimicrob Agents and Chemother.2005; 49(5): 2151.
7.
HolbrookA.M., PereiraJ.A., LabirisR., McDonaldH.Systematic overview of warfarin and its drug and food interactions.Arch Intern Med.2005; 165: 1095–1106.
8.
StewartD., HelmsP., McCaigD., BondC.Monitoring adverse drug reactions in children using community pharmacies: a pilot study.Br J Clin Pharmacol.2005; 59(60: 677–683.
9.
HongS.H., SpadaroD., WestD., TakS.H.Patient valuation of pharmacist services for self care with OTC medications.J Clin Pharm Ther.2005; 30: 193–199.
10.
PignoneM., SahaS., HoergerT., LohrK.N.Challenges in systematic reviews of economic analyses.Ann Intern Med.2005; 142: 1073–1079.
11.
OliphantC.M., ScheetzM.H.Current issues in gram-negative resistance: mechanism and treatment of resistant gram negative pathogens.Adv Pharm.2005; 3(2): 119–130.
12.
HolsclawS.L., OlsonK.I., HornakR., DenhamA.M.Assessment of patient satisfaction with telephone and mail interventions provided by a clinical pharmacy cardiac risk reduction service.J Manag Care Pharm.2005; 11(5): 403–409.
13.
CaggianoV., WeissR.V., RickertT.S., Linde-ZwirbleW.T.Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.Cancer.2005; 103: 1916–1924.
14.
VoulgariP.V., AlamanosY., NikasS.N., BougiasD.V.Infliximab therapy in established rheumatoid arthritis: an observational study.Am J Med.2005; 118(5): 515–520.
15.
SantaguidaP.L., HelfandM., RainaP.Challenges in systematic reviews that evaluate drug efficacy or effectiveness.Ann Intern Med.2005; 142: 1066–1072.
